Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
KPRX Stock Chart & Stats
$1.91
-$0.13(-3.22%)
At close: 4:00 PM EST
$1.91
-$0.13(-3.22%)
Day’s Range― - ―
52-Week Range$1.76 - $4.18
Previous CloseN/A
Volume13.46K
Average Volume (3M)36.18K
Market Cap
$7.62M
Enterprise Value-$1.23M
Total Cash (Recent Filing)$17.09M
Total Debt (Recent Filing)$368.26K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 08, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding3,950,628
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit25.23
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$12.00Price Target Upside528.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.23
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseExtremely low leverage and a meaningful equity cushion reduce solvency risk and give management flexibility to fund R&D or tolerate clinical setbacks. This structural balance-sheet strength lengthens runway versus highly levered peers and supports strategic partnerships over the next several quarters.
Prior Profitable 2024 Results Signal Commercialization PotentialA prior year showing revenue generation and net income demonstrates the company can monetize assets or transactions and is not purely a pre-revenue lab. That historical ability to produce positive results provides a tangible pathway to recurring revenue if clinical candidates are advanced or licensed.
Access To Capital Via $100M Mixed Securities ShelfA registered $100M shelf is a structural financing tool enabling equity or debt issuance as needed to fund trials and operations. This formal access to capital lowers immediate liquidity pressure, permitting multi-quarter clinical programs and partnerships without urgent one-off financings.
Bears Say
High Cash Burn And Negative Operating/free Cash FlowSustained negative operating and free cash flow erodes cash reserves and forces reliance on external funding. Over several quarters this increases dilution risk, limits optionality for R&D prioritization, and can pressure trial timelines and partner negotiations absent firm near-term revenue.
TTM Revenue Collapse And Large Net LossA reversion to zero reported revenue and a sizeable TTM loss highlights volatile, non-recurring revenue dynamics typical of early-stage biotech. This undermines predictable cash flow generation, heightens execution and commercialization risk, and increases dependence on financing or milestone-based deals.
Shelf Filing Implies Dilution/funding Overhang RiskWhile the shelf provides funding optionality, it also creates a durable overhang risk: management can issue equity or other securities, which may dilute existing holders and alter capital structure. That structural financing channel raises medium-term dilution and governance considerations.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.76 and its highest was $4.18 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $7.62M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is May 08, 2026 which is in 37 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Mar 25, 2026. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of -$0.67 by -$0.92.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.71.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 3,950,628 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$1.59 in its last earnings report, missing expectations of -$0.67. Following the earnings report the stock price went down -0.971%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(528.27% Upside)
Technical Analysis
Genprex
―
Dogwood Therapeutics
―
Sensei Biotherapeutics
―
TransCode Therapeutics
―
AEON Biopharma
―
Ownership Overview
3.78% Insiders
1.08% Mutual Funds
16.13% Other Institutional Investors
78.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---